Monofer Dosing for Iron Deficiency Anemia
For adults weighing ≥50 kg, administer 1,000 mg of Monofer as a single intravenous infusion over at least 20 minutes; for adults <50 kg, administer 20 mg/kg as a single dose. 1
Adult Dosing
The FDA-approved dosing for Monofer (ferric derisomaltose/iron isomaltoside) is straightforward and weight-based:
- ≥50 kg body weight: 1,000 mg IV infusion over ≥20 minutes as a single dose
- <50 kg body weight: 20 mg/kg actual body weight IV infusion over ≥20 minutes as a single dose
- Repeat dosing: Administer again only if iron deficiency anemia recurs 1
This represents a significant advantage over older formulations—Monofer can deliver the total iron deficit in a single, rapid infusion without requiring a test dose 2, 3. The maximum single dose is 20 mg/kg body weight, which allows for complete iron repletion in one visit for most patients 2.
Preparation Requirements
Critical safety consideration: Only administer when personnel and therapies for treating serious hypersensitivity reactions are immediately available 1. Monitor patients for at least 30 minutes after infusion completion and until clinically stable 1.
Dilute the appropriate volume in 100-500 mL of 0.9% sodium chloride (final concentration >1 mg iron/mL). The diluted solution is stable for up to 8 hours at room temperature 1.
Pediatric Dosing
No IV iron preparation is currently approved for pediatric use in Europe 4. However, in the USA, iron sucrose is approved from age 2 years and iron gluconate from age 6 years for chronic kidney disease patients 4.
For children requiring parenteral iron on long-term parenteral nutrition, the recommended daily dose is 200-250 mcg/kg/day in preterm infants and 50-100 mcg/kg/day (maximum 5 mg/day) in infants and children 4.
Recent pediatric data suggest that for oral iron polymaltose complex in children with CKD, doses effectively improved iron status, though specific Monofer pediatric dosing remains off-label 5.
Clinical Context and Indications
Monofer is specifically indicated for adults with:
- Intolerance to oral iron or unsatisfactory response to oral iron
- Non-hemodialysis dependent chronic kidney disease 1
When to choose IV over oral iron: Intravenous iron should be first-line in patients with clinically active inflammatory bowel disease, previous oral iron intolerance, hemoglobin <10 g/dL, or those requiring erythropoiesis-stimulating agents 6. For IBD patients specifically, body weight-based dosing recommendations exist: 1,000-1,500 mg for Hb 10-12 g/dL (women) or 10-13 g/dL (men) depending on weight, and 1,500-2,000 mg for Hb 7-10 g/dL 6.
Safety Profile
Serious hypersensitivity reactions occurred in 0.3% of patients in clinical trials 1. Unlike iron dextran, no test dose is required for Monofer due to its linear, unbranched isomaltoside structure with low immunogenic potential 3. This is a major practical advantage over iron dextran, which requires a 25 mg test dose and carries higher anaphylaxis risk 7.
The tightly bound iron matrix structure results in controlled, slow release of bioavailable iron with minimal labile iron release, reducing toxicity risk 2, 3.
Monitoring
Monitor hemoglobin, hematocrit, serum ferritin, and transferrin saturation during therapy. Do not administer to patients with iron overload (ferritin >800 μg/L or transferrin saturation >50% should be used as upper limits) 6, 1.